PD-L1 expression
-
May 30, 2020
FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC Bookmark
George Lundberg, MDArticle from OncLive curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.
Go to full article published by OncLive.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
June 24, 2019
FDA Expands Pembrolizumab Indication for First-Line Treatment of NSCLC (Tps ≥1%) Bookmark
Emma Shtivelman, PhDExcerpt:
“On April 11, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1%) determined by an FDA-approved test.
“Pembrolizumab was previously approved as a single agent for the first-line treatment of patients with metastatic NSCLC whose tumors express PD-L1 TPS ≥50%.”
Go to full article published by the U.S. Food and Drug Administration on April 11, 2019.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 1, 2018
Pembrolizumab Alone or With Chemotherapy for PD-L1–Positive NSCLC? Bookmark
Emma Shtivelman, PhDExcerpt from Cancer Network:
“Researchers found that in patients with non–small-cell lung cancer (NSCLC) and a Tumor Proportion Score (TPS) ≥ 50, pembrolizumab plus chemotherapy failed to improve overall survival (OS) or progression-free survival (PFS) compared with pembrolizumab alone.
“Results from the study were presented in a poster presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer, held September 23–26 in Toronto.”
Go to full article published by Cancer Network on Sep 24, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 5, 2018
FDA Grants Priority Review to Keytruda Plus Chemotherapy for Lung Cancer Subtype Bookmark
Emma Shtivelman, PhDExcerpt from Healio:
“The FDA granted priority review designation to a supplemental biologics license application that seeks approval of pembrolizumab for use in combination with chemotherapy as first-line treatment of metastatic squamous non-small cell lung cancer regardless of PD-L1 expression.
“The agency set a target action date of Oct. 30.”
Go to full article published by Healio on July 2, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
April 26, 2018
Predicting If an Immune Checkpoint Drug Will Work
Emma Shtivelman, PhDDrugs that activate the immune system to attack cancer in a process known as immune checkpoint blockade (ICB) are a focus of intense investigation. A number of them are already approved by the U.S. Food and Drug Administration (FDA) for various cancers; namely, the anti-CTLA4 antibody ipilimumab (Yervoy), two anti-PD-1 antibodies: pembrolizumab (Keytruda) and nivolumab (Opdivo), and three anti-PD-L1 drugs: atezolizumab (Tecentriq), avelumab (Bavencio)… Read more »
-
November 10, 2016
War of the Checkpoint Inhibitors: Anti-PD-1 Drugs Move into First-Line Treatment in NSCLC
Emma Shtivelman, PhDLast year, the U.S. Food and Drug Administration (FDA) approved two anti-PD-1 checkpoint inhibitors, a type of immunotherapy, for treatment of non-small cell lung cancer (NSCLC) in patients whose cancer has progressed after first-line treatment with chemotherapy. Now, the manufacturers of both drugs, pembrolizumab (made by Merck) and nivolumab (made by Bristol-Myers Squibb; BMS) are intent on expanding the indications for use of their… Read more »
-
September 9, 2015
To PD-L1 or Not to PD-L1: That Is the Question
Emma Shtivelman, PhDThese days, it seems that I write mostly about immune checkpoint blockade drugs, or some other new immunotherapy treatment for cancer. This post is no different—it covers PD-L1, a protein that is at the center of clinical decisions for selecting patients who are likely to benefit from treatment with an anti-PD-1 or anti-PD-L1 drug.